Lafora Disease (Unverricht Disease) – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Lafora Disease (Unverricht Disease) – Drugs In Development, 2024 report and make more profitable business decisions.
Unverricht-Lundborg disease (EPM1) a rare and fatal genetic neurodegenerative disorder that causes progressive myoclonic epilepsy. It is caused by mutations of the cystatin B gene. It typically presents in adolescents with new onset seizures along with symptoms such as lack of motor coordination, impaired mental function, and depression. It is diagnosed with a skin biopsy that shows Lafora bodies in the cells of a patient’s sweat ducts. Anti-seizure medications (ASMs) are used to treat seizures and myoclonus.
The Lafora Disease (Unverricht Disease) drugs in development market research report provide comprehensive information on the therapeutics under development for Lafora Disease (Unverricht Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Lafora Disease (Unverricht Disease) and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Lafora Disease (Unverricht Disease) | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 7 molecules, with 6 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Lafora Disease (Unverricht Disease) therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Lafora Disease (Unverricht Disease) pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Lafora Disease (Unverricht Disease) treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
ANLBio Co LtdCenter for Biomedical Research for Neurodegenetive Diseases
Ionis Pharmaceuticals Inc
Taysha Gene Therapies Inc
Valerion Therapeutics LLC (Inactive)
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Lafora Disease (Unverricht Disease) reports